• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Spiral helical welded steel pipe
Biotech

Lilly drops 3 clinical programs, including Prevail gene therapy

Lilly discontinued its GRN gene therapy in frontotemporal dementia "due to a lack of compelling efficacy," a spokesperson told Fierce.
Gabrielle Masson Feb 4, 2026 12:33pm
Capitol Building and Congress
Favicon Fierce Pharma

FDA’s rare pediatric voucher program revived by funding bill

Feb 4, 2026 3:12pm
Inside Henlius global growth strategy
Sponsored

Inside Henlius’ global growth strategy

Feb 2, 2026 8:00am
reshuffle pipeline target reorganize shift change

Novartis nixes 6 ph. 1 assets, adds 2 new cancer candidates

Feb 4, 2026 12:09pm
Miels

GSK's new CEO looking for $2B-$4B deals 'hiding in plain sight'

Feb 4, 2026 7:25am
three spotlights on a stage

Jay Bhattacharya faces Senate grilling on NIH disruptions

Feb 3, 2026 5:20pm
More News

Preclinical stem cell biotech takes SPAC route to Nasdaq

Feb 4, 2026 10:15am

Amgen eyes lupus redemption while cancer candidate struggles

Feb 4, 2026 6:10am

Novo 'wishes Pfizer luck' with Metsera drug, seeks monthly GLP-1

Feb 4, 2026 5:09am

HHS launches $100M prize to develop antiviral therapies

Feb 3, 2026 4:00pm
See more stories
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings